December 23, 2021
Appili Therapeutics – Press Release Correction
December 22, 2021
Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
November 19, 2021
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
November 12, 2021
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
November 12, 2021
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
October 14, 2021
Appili Therapeutics Announces Closing of Public Offering of $7,000,220
October 7, 2021
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
October 6, 2021
Appili Therapeutics Announces Overnight Marketed Equity Offering
September 29, 2021
Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction
September 23, 2021
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
September 20, 2021
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
September 17, 2021
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub-Study for Mild-to-Moderate COVID-19 Patients
September 8, 2021
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
August 18, 2021
Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement
August 13, 2021
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022
August 9, 2021
Appili Therapeutics Secures $3.5 Million in Funding
June 24, 2021
Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results Provides Update on Strategy for Fiscal 2022
June 17, 2021
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
May 17, 2021
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients
April 19, 2021
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021